Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Get Free Report) fell 6.6% during mid-day trading on Thursday . The company traded as low as $16.40 and last traded at $16.54. 41,878 shares traded hands during trading, a decline of 89% from the average session volume of 374,995 shares. The stock had previously closed at $17.71.
Wall Street Analysts Forecast Growth
KYTX has been the subject of a number of research analyst reports. Wells Fargo & Company assumed coverage on shares of Kyverna Therapeutics in a research report on Monday, March 4th. They set an “overweight” rating and a $44.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on shares of Kyverna Therapeutics in a research note on Monday, March 4th. They set an “overweight” rating and a $39.00 target price for the company. SVB Leerink started coverage on Kyverna Therapeutics in a research note on Monday, March 4th. They set an “outperform” rating and a $48.00 price target on the stock. Leerink Partnrs restated an “outperform” rating on shares of Kyverna Therapeutics in a research note on Monday, March 4th. Finally, Morgan Stanley assumed coverage on shares of Kyverna Therapeutics in a research report on Monday, March 4th. They set an “overweight” rating and a $40.00 price target for the company. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $42.75.
View Our Latest Stock Analysis on Kyverna Therapeutics
Kyverna Therapeutics Price Performance
Insider Buying and Selling
In other news, major shareholder Northpond Ventures Iii Gp, Llc bought 450,000 shares of Kyverna Therapeutics stock in a transaction that occurred on Monday, February 12th. The stock was purchased at an average cost of $22.00 per share, with a total value of $9,900,000.00. Following the completion of the transaction, the insider now directly owns 450,000 shares in the company, valued at $9,900,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Kyverna Therapeutics Company Profile
Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.
Featured Articles
- Five stocks we like better than Kyverna Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Hasbro’s Management Made All the Right Calls This Quarter
- There Are Different Types of Stock To Invest In
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.